DUNFERMLINE, Scotland–()–Optos Plc, a subsidiary of Nikon Corporation, Japan and the only
ultra-widefield retinal imaging company for eye care is pleased to
announce an exclusive distribution agreement in Europe and Australia for
MacuLogix and LumiThera products. By entering this arrangement, we now
offer a comprehensive solution to visualize, identify, and treat
age-related macular degeneration (AMD), one of the leading causes of
blindness in the world.

This three-part offering includes ultra-widefield optomap®
colour and autofluorescence retinal images to show the structure and
function of the retinal pigment epithelium (RPE) where AMD manifests
within the eye. The MacuLogix AdaptDx, a dark adaptometer that can be
used to detect AMD at a subclinical stage at least three years before
structural changes such as drusen are visible. And the LumiThera’s Valeda
Light Delivery System, the first approved for treatment for dry
age-related macular degeneration using photobiomodulation.

We are pleased to enter this relationship with MacuLogix and LumiThera
to combat AMD. This strategic solution to monitor and treat AMD is very
important for the patients who have this complicated, degenerative
disease”, stated Robert Kennedy, Chief Executive Officer, Optos. “We
believe these two companies have complementary products to
ultra-widefield retinal imaging that would provide a differentiated
offering for AMD patients. The MacuLogix device can early diagnose AMD
and the Lumithera medical device offers a differentiated treatment path”.

Optos is one of the largest and most-respected suppliers of
retina-focused medical devices in the world and MacuLogix is extremely
honored to enter into this international partnership with them,” said
William McPhee, President and CEO of MacuLogix. “By expanding our
distribution network to include these eight countries, the AdaptDx will
reach an additional 260 million people. Partnering with the Optos team
gets us one step closer to our company’s vision of eliminating blindness
caused by AMD.”

Clark Tedford, Ph.D., LumiThera President and CEO stated, “The
distribution agreement with Optos allows LumiThera to begin
commercialization throughout Europe and establishes a collaboration with
a partner in the retinal imaging area. Optos is the global leader in
ultra-widefield retinal imaging technologies and we are honored to be
working with them to open up a new age in the treatment of AMD.”

About MacuLogix, Inc.

MacuLogix® equips eye care professionals with the
instrument, tools and education needed to effectively diagnose and treat
patients with AMD. By leveraging the science of dark adaptation through
its AdaptDx®, MacuLogix is working to eliminate preventable
blindness caused by AMD, a chronic, progressive disease that impacts
over 170 million people worldwide and goes undiagnosed in 25 percent of
patients. Through its AdaptDx® dark adaptation biomarker,
MacuLogix enables eye care professionals to detect, monitor and treat
AMD three years before it can be seen clinically. MacuLogix provides
in-practice training and treatment best practices to support the
implementation and optimization of the AdaptDx®. Visit www.maculogix.com
for additional information.

About LumiThera, Inc.

LumiThera is a commercial-stage medical device company focused on
treating people affected by ocular disorders and diseases including dry
AMD, a leading cause of blindness in adults over 65. The Company is a
leader in the use of photobiomodulation for the treatment of acute and
chronic ocular diseases and disorders. The Company is developing the
office-based Valeda™ Light Delivery System to be used by eye care
specialists as medical treatments.

The device has been granted authorization to use the CE Mark by a EU
Notified Body as required for commercial use in the European Union only.
Valeda™ is not approved for use by the Food & Drug Administration (FDA)
in the USA. Visit www.lumithera.com
for additional information about the company.

About Optos

Optos is the leading ultra-widefield retinal imaging company, acquired
by Nikon in 2015. Its core technology, ultra-widefield (UWF™) high
resolution digital images (optomap®) capture
approximately 82% and 200 of the retina, something no other
device is capable of doing in a single image. In 2018, the company
announced a new product offering that combines ultra-widefield retinal
imaging and optical coherence tomography (OCT) scans. For more
information about Optos, please visit www.optos.com.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *